Buoyant Sanofi signs Denali deal

1 November 2018
2019_biotech_test_vial_discovery_big

Fresh from presenting some of the most encouraging  quarterly results in recent memory, Sanofi (Euronext: SAN) has taken another bet on increasing its future revenues.

The French pharma major is spending $125 million upfront and potentially more than $1 billion in milestone payments on a collaboration with US biotech firm Denali Therapeutics (Nasdaq: DNLI), shares in which opened 9% higher on Thursday.

The collaboration will focus on developing treatments for neurological and inflammatory diseases, with a focus in particular on two lead molecules that target a critical signaling protein known as the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology